This indication is approved under accelerated approval based on overall response rate and duration of response.Rar! Ï s ³ÿt €4²I?´ Ò¥æÁ ¬d. OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. It’s approved by the Food and Drug Administration (FDA) to treat certain types of metastatic non-small cell lung cancer. Opdivo (nivolumab) is a prescription brand-name medication.
r]vÇ°Ê~ig€ðï †àV Ĥ„†‹%ã:†Rà° B*A«º ÈËA¨ Õwdûph /Filter /FlateDecode /FormType 1 /Length 15 /Matrix /Resources 8 0 R > stream xÚÓ ÎP(Îà ý ðendstream endobj 9 0 obj /Type /XObject /Subtype /Form /BBox /Filter /FlateDecode /FormType 1 /Length 15 /Matrix /Resources 10 0 R > stream xÚÓ ÎP(Îà ý ðendstream endobj.
0 kommentar(er)
